Late-breaking presentation of data from the OSIRIS IIT PoC study of oral orismilast in hidradenitis suppurativa (HS) at the European Academy of Dermatology and Venerology Congress 2023 Additional e-posters on the efficacy and safety of orismilast in moderate-to-severe psoriasis from the IASOS Phase 2b study and biomarker analyses from the skin of patients in the IASOS study, will be presented Positive topline data from the IASOS study was reported early January 2023 and for the OSIRIS study in June 2023
HELLERUP, Denmark, Oct. 6, 2023 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced acceptance of a late-breaking oral presentation at the European Academy of Dermatology and Venerology (EADV) Congress 2023 on October 11-14, 2023, in Berlin, Germany. New data from the OSIRIS investigator-initiated (IIT) proof of concept open label, single center study of oral orismilast in HS will be presented by the investigator Professor, Dr. Gregor Jemec. Additionally, two e-posters from the IASOS Phase 2b study will be presented at the EADV Congress 2023, describing the clinical efficacy and safety of orismilast and its impact on biomarkers measured in the skin of moderate-to-severe psoriasis patients. Oral presentation details
Date and time: Thursday, October 12, 2023, at 16:30-16:45 CEST
Authors: James G. Krueger, Richard B. Warren, Emma Guttman-Yassky
Poster title: Significant improvements in signs and symptoms with orismilast in moderate-to-severe psoriasis: Efficacy, safety and sub-analyses from the Phase 2b IASOS trial Authors: Richard B. Warren, Lars E. French, Andrew Blauvelt
Professor Gregor B. Jemec, PhD, MD, Founding Chairman of the Department of Dermatology, Zealand University Hospital Roskilde, Denmark and sponsoring investigator of the study says: "A strong unmet need remains for a safe and effective oral treatment for hidradenitis suppurativa. The promising topline results from the OSIRIS study illustrates that potent PDE4 inhibition by orismilast offers the potential for additional efficacy in combination with a well-known safety profile from the PDE4 class." "We are pleased that results from the OSIRIS IIT PoC study have been selected as a late-breaking presentation at the EADV Congress 2023. Additionally, we are super excited about presenting two posters with new data on orismilast at the Congress. The data presented at EADV demonstrate the attractive profile of orismilast and its potential to be a first or best-in-class candidate for the treatment of atopic dermatitis, hidradenitis suppurativa and psoriasis. We look forward to the results being shared and discussed with the leading experts in the field." The FDA has cleared UNION's Investigational New Drug (IND) application for oral orismilast and granted Fast Track designation for oral orismilast for the treatment of moderate to severe AD as well as for the treatment of moderate to severe HS. In 2021, UNION entered a strategic partnership with Innovent Biologics for the development of orismilast in Mainland China, Hong Kong, Macau, and Taiwan. Silverberg J.I. et al., Pharmacology of orismilast, a potent and selective PDE4 inhibitorPDE4 inhibitor, JEADV 2022: https://onlinelibrary-wiley-com.libproxy1.nus.edu.sg/doi/10.1111/jdv.18818 Warren R.B. et al., Efficacy and safety in moderate-severe psoriasis and development of modified release tablets, JEADV 2022: https://onlinelibrary-wiley-com.libproxy1.nus.edu.sg/doi/10.1111/jdv.18812 UNION therapeutics is a privately held, mid- to late-stage, pharmaceutical development company advancing novel treatment options within immunology and infectious diseases, two large and fast-growing therapeutic areas. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at www.uniontherapeutics.com SOURCE UNION therapeutics